Indoco Remedies Ltd

Indoco Remedies has entered into a Sale Agreement and Lease Agreement on 29 August 2025 for sale and lease back of part of the Company's movable properties at its Waluj Facility located at B-19 MIDC, Waluj, Aurangabad, Maharashtra - 431136 (Waluj Facility) and AnaCipher Clinical Research Organisation located at 2nd, 3rd & 4th Floor, Mirrakamshetty Mall, Opp. Doordarshan Bhavan, Ramanthapur Medchal-Malkajgiri District, Hyderabad - 500013, Telangana (CRO) on the terms and conditions as mentioned therein. The sale of the aforesaid movable properties will not have any impact on the manufacturing or business of the Company, as the Company will continue to use the said movable properties on lease basis. Powered by Capital Market - Live

Indoco Remedies announced that the Annual General Meeting(AGM) of the company will be held on 11 September 2025.Powered by Capital Market - Live

The approval covers strengths of 2.5 mg, 10 mg, 15 mg, and 20 mg. The approved tablets are bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD), Xarelto Tablets, manufactured by Janssen Pharmaceuticals, Inc. The product will be manufactured at Indoco's facility in Verna Industrial Area, Goa (L-14, Verna, Goa ' 403722). Rivaroxaban is an oral anticoagulant used for the treatment and prevention of venous thromboembolism (VTE) ' a serious condition involving blood clots in the veins, which can lead to complications such as pulmonary embolism. Commenting on the development, Aditi Panandikar, managing director of Indoco Remedies, said, 'Besides reflecting the capability of Indoco Remedies to deliver products of high-quality standards, this development also provides impetus to our growth aspirations in an important market such as the US.' Indoco Remedies is engaged in the manufacturing and marketing of formulations (finished dosage forms) and active pharmaceutical ingredients (APIs). The company had reported a consolidated net loss of Rs 40.39 crore in the quarter ended March 2025 as against net profit of Rs 22.70 crore during the previous quarter ended March 2024. Sales declined by 12.57% to Rs 383.89 crore in Q4 FY25 over Q4 FY24.Powered by Capital Market - Live

Indoco Remedies announced final approval of the Company's Abbreviated New Drug Application (ANDA) for Rivaroxaban Tablets USP, 2.5 mg, 10 mg, 15 mg and 20 mg, to market a generic equivalent to the reference listed drug (RLD), Xarelto Tablets, 2.5 mg, 10 mg, 15 mg and 20 mg, of Janssen Pharmaceuticals, Inc. (Janssen), from USFDA. Rivaroxaban Tablets USP, 2.5 mg, 10 mg, 15 mg and 20 mg are bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Xarelto Tablets, 2.5 mg, 10 mg, 15 mg and 20 mg, of Janssen Pharmaceuticals, Inc. (Janssen). Rivaroxaban Tablets USP, will be manufactured by Indoco Remedies Limited, at their manufacturing facility located at L-14, Verna Industrial Area, Verna, Goa ' 403722 in India. Rivaroxaban is used for the treatment of venous thromboembolism (VTE). Powered by Capital Market - Live

Net loss of Indoco Remedies reported to Rs 35.79 crore in the quarter ended June 2025 as against net profit of Rs 2.62 crore during the previous quarter ended June 2024. Sales rose 1.13% to Rs 429.08 crore in the quarter ended June 2025 as against Rs 424.29 crore during the previous quarter ended June 2024. ParticularsQuarter EndedJun. 2025Jun. 2024% Var. Sales429.08424.29 1 OPM %4.0911.26 - PBDT-6.9634.49 PL PBT-36.666.97 PL NP-35.792.62 PL Powered by Capital Market - Live

The said unit is located at L32, 33 and 34, Verna Industrial Estate, South Goa. The EU GMP certification issued by the European Health Authorities confirms that the site complies with the good manufacturing practice requirements. Aditi Panandikar, managing director, Indoco Remedies, said: This GMP certification for our sterile drug product manufacturing facility, Goa Plant II is a testament to our relentless efforts to supply quality and affordable medicines across geographies. We remain fully committed to adhering to cGMP standards and consistently delivering quality products to customers and patients worldwide. Indoco Remedies is engaged in the manufacturing and marketing of formulations (finished dosage forms) and active pharmaceutical ingredients (APIs). The company had reported a consolidated net loss of Rs 40.39 crore in the quarter ended March 2025 as against net profit of Rs 22.70 crore during the previous quarter ended March 2024. Sales declined by 12.57% to Rs 383.89 crore in Q4 FY25 over Q4 FY24. Powered by Capital Market - Live

Indoco Remedies has received Certificate for EU Good Manufacturing Practices (GMP) Compliance from the European Health Authorities for its sterile drug product manufacturing facility, Goa Plant II located at L32, 33 and 34, Verna Industrial Estate, South Goa-403722.Powered by Capital Market - Live

Indoco Remedies will hold a meeting of the Board of Directors of the Company on 24 July 2025.Powered by Capital Market - Live

 Indoco Remedies announced final approval of Allopurinol Tablets USP, 200 mg through Company's Abbreviated New Drug Application (ANDA) for Allopurinol Tablets USP to market a generic equivalent to the reference listed drug (RLD), ZYLOPRIM 200 mg of Casper Pharma LLC from USFDA.Powered by Capital Market - Live

Allopurinol is used to prevent or lower high uric acid levels in the blood. It is also used to prevent or lower excess uric acid levels caused by cancer medicines or in patients with kidney stones. The drug is the generic equivalent of the reference listed drug (RLD), Zyloprim, marketed by Casper Pharma LLC. Indoco Remedies is engaged in the manufacturing and marketing of formulations (finished dosage forms) and active pharmaceutical ingredients (APIs). The pharmaceutical company reported a standalone net loss of Rs 10.23 crore in Q3 FY25 as against a net profit of Rs 20.01 crore posted in Q3 FY24. Revenue from operations stood at Rs 364.91 crore in the third quarter of FY25, down 18.61% as against Rs 448.38 crore posted in Q3 FY24. Powered by Capital Market - Live